- ICH GCP
- US-Register für klinische Studien
- Klinische Studie NCT07951333
Targeted Quality Improvement Trial to Improve Post-Discharge VTE
Targeted Quality Improvement Trial to Improve Post-Discharge VTE Chemoprophylaxis After Abdominal and Pelvic Cancer Surgery
Venous thromboembolism (VTE) is the most common preventable cause of death after major abdominal and pelvic cancer surgery, and over one-third of events occur after discharge. National guidelines recommend extended post-discharge chemoprophylaxis, but hospital adherence varies widely. This observational study has two parts. Aim 1 uses interviews, focus groups, and surveys with patients, clinicians, and health system stakeholders to identify barriers and facilitators to implementing a post-discharge VTE chemoprophylaxis quality improvement project. Aim 2 uses retrospective hospital- and population-level data and coincidence analysis to identify hospital performance phenotypes and develop targeted implementation strategies. Findings will inform a separately registered stepped-wedge implementation trial (Aim 3).
Studienübersicht
Status
Bedingungen
Detaillierte Beschreibung
Aim 1: Semi-structured interviews, focus groups, and electronic surveys will be conducted with patients (n≈20) undergoing abdominal or pelvic cancer surgery, clinicians (n≈20), and health system stakeholders (n≈10). Surveys include study-specific VTE chemoprophylaxis and ordering surveys, the Organizational Readiness to Change Assessment (ORCA), and the Safety Attitudes Questionnaire (SAQ). Interviews are audio-recorded, transcribed, de-identified, and analyzed with hybrid inductive and deductive coding mapped to CFIR domains. Patient eligibility is screened through the medical record; screening data are not linked to survey or interview responses.
Aim 2: De-identified, retrospective hospital- and population-level data (demographics, procedure details, VTE prophylaxis orders, VTE outcomes), obtained through the University of Chicago Center for Research Informatics, will be analyzed using coincidence analysis (CNA) to identify causal pathways, define low- and high-performance hospital phenotypes, and develop targeted implementation strategies. Aim 2 data are kept separate from Aim 1 recruitment data.
This record covers Aims 1 and 2 only. The Aim 3 stepped-wedge trial is registered separately
Studientyp
Einschreibung (Geschätzt)
Kontakte und Standorte
Studienorte
-
-
Illinois
-
Chicago, Illinois, Vereinigte Staaten, 60637
- University of Chicago
-
Kontakt:
- Jacob Ryno, MPH
- Telefonnummer: 314-520-0355
- E-Mail: jryno@uchicago.edu
-
Hauptermittler:
- Ryan P Merkow, MD, MS
-
-
Teilnahmekriterien
Zulassungskriterien
Studienberechtigtes Alter
Akzeptiert gesunde Freiwillige
Studienberechtigte Geschlechter
Probenahmeverfahren
Studienpopulation
Patients, clinicians, and health system stakeholders involved in abdominal and pelvic cancer surgery care, plus a retrospective hospital-level dataset.
Beschreibung
Inclusion Criteria:
- Patients: adults (18-85) undergoing abdominal and/or pelvic cancer surgery; English-speaking
- Clinicians: faculty and fellow physicians, advanced practice providers, physician assistants, medical assistants, dietitians, and social workers in participating surgical service clinics; English-speaking
- Stakeholders: Chief Medical Officer, Chief Information Officer, Chief Quality Officer, or related leadership
Aim 2: records of patients undergoing abdominal or pelvic cancer surgery between 1/1/2006 and 9/16/2025
Exclusion Criteria:
- Non-English-speaking individuals
- Patients not undergoing abdominal or pelvic cancer surgery
- Individuals under 18
Studienplan
Wie ist die Studie aufgebaut?
Designdetails
- Beobachtungsmodelle: OTHER
- Zeitperspektiven: OTHER
Kohorten und Interventionen
Gruppe / Kohorte |
|---|
|
Patients
Adults undergoing abdominal or pelvic cancer surgery at the University of Chicago Medical Center, interviewed or surveyed about post-discharge VTE chemoprophylaxis. |
|
Clinicians
Surgeons, advanced practice providers, nurses, and other clinical staff who care for abdominal and pelvic cancer surgery patients, interviewed or surveyed. |
|
Health System Stakeholders
Chief Medical, Information (or Medical Information), and Quality Officers and related leadership, interviewed. |
|
Retrospective Hospital/Patient Dataset (Aim 2)
De-identified, hospital- and population-level records of abdominal and pelvic cancer surgery patients, 2006-2025 |
Was misst die Studie?
Primäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
Barriers and facilitators to post-discharge VTE chemoprophylaxis implementation
Zeitfenster: Year 1 and 2; Single interview or focus group session (30-60 minutes), at enrollment.
|
Themes identified from interviews and focus groups, coded and mapped to CFIR domains |
Year 1 and 2; Single interview or focus group session (30-60 minutes), at enrollment.
|
Sekundäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
Organizational readiness to change (ORCA score)
Zeitfenster: Year 1 and 2; Single survey at enrollment.
|
Survey scores, dichotomized as low or high |
Year 1 and 2; Single survey at enrollment.
|
|
Safety and quality culture (SAQ score)
Zeitfenster: Year 1 and 2; Single survey at enrollment.
|
Survey scores, dichotomized as low or high. |
Year 1 and 2; Single survey at enrollment.
|
|
VTE chemoprophylaxis ordering patterns
Zeitfenster: Year 1 and 2; Single survey at enrollment.
|
Survey responses on type of prophylaxis prescribed, reasoning, and risk factors. |
Year 1 and 2; Single survey at enrollment.
|
|
Hospital performance phenotypes
Zeitfenster: Year 3; Following AIM 2 completion.
|
Number and characteristics of low- and high-performance phenotypes identified by coincidence analysis of Aim 1 and retrospective data. |
Year 3; Following AIM 2 completion.
|
Mitarbeiter und Ermittler
Sponsor
Ermittler
- Hauptermittler: Ryan Merkow, MS, MD, University of Chicago
Studienaufzeichnungsdaten
Haupttermine studieren
Studienbeginn (Geschätzt)
Primärer Abschluss (Geschätzt)
Studienabschluss (Geschätzt)
Studienanmeldedaten
Zuerst eingereicht
Zuerst eingereicht, das die QC-Kriterien erfüllt hat
Zuerst gepostet (Tatsächlich)
Studienaufzeichnungsaktualisierungen
Letztes Update gepostet (Tatsächlich)
Letztes eingereichtes Update, das die QC-Kriterien erfüllt
Zuletzt verifiziert
Mehr Informationen
Begriffe im Zusammenhang mit dieser Studie
Schlüsselwörter
Zusätzliche relevante MeSH-Bedingungen
Andere Studien-ID-Nummern
- IRB25-1360
- R01HL183429 (US NIH Stipendium/Vertrag)
- IRB25-1360 (Andere Kennung: UChicago IRB)
Plan für individuelle Teilnehmerdaten (IPD)
Planen Sie, individuelle Teilnehmerdaten (IPD) zu teilen?
Beschreibung des IPD-Plans
Qualitative recordings and transcripts will not be shared. De-identified data will be retained in secure University of Chicago storage, and any external sharing would require IRB review
Arzneimittel- und Geräteinformationen, Studienunterlagen
Studiert ein von der US-amerikanischen FDA reguliertes Arzneimittelprodukt
Studiert ein von der US-amerikanischen FDA reguliertes Geräteprodukt
Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .